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Objective: The present study was undertaken to demonstrate that limited pulmonary
resection for peripheral small-sized lung cancer yields outcomes not inferior to those
of lobectomy.
Methods: During the 9-year period from 1992 to 2000, patients with cT1 N0 M0
peripheral non–small cell lung cancer whose maximum tumor diameter was 2 cm or
less on diagnostic imaging and in whom lobectomy was determined to be feasible
were treated with limited resection if the patient consented to the procedure and with
lobectomy if consent to limited resection was not obtained. The survival and clinical
outcome of the patients whose tumors were postoperatively staged as pT1 N0 M0
were compared between the limited resection group (n  74) and the lobectomy
group (n  159).
Results: The limited resection group consisted of 60 patients treated with segmen-
tectomy and 14 patients treated with wedge resection. Among patients followed up
for a mean period of 52 months after the operation, neither the 3-year nor 5-year
survivals differed significantly between the limited resection group (3-year survival,
94.0%; 5-year survival, 89.1%) and the lobectomy group (3-year survival, 97.0%;
5-year survival, 90.1%). Postoperative tumor recurrence was noted in 5 patients
after limited resection and in 9 patients after lobectomy, and the difference in the
incidence of postoperative recurrence between the 2 groups was not significant.
Conclusions: The results of this study indicate that in patients with peripheral T1 N0
M0 non–small cell lung cancer whose maximum tumor diameter was 2 cm or less,
the outcome of limited pulmonary resection is comparable with that of pulmonary
lobectomy.
Although lobectomy is often used as the surgical procedure to treatT1 N0 non–small cell lung cancer (NSCLC), lesser pulmonaryresection, such as segmentectomy or wedge resection, has theo-retical advantages in terms of the ability of patients to withstandfurther pulmonary resection in the future if a second primary lungcancer should develop and the need to preserve pulmonary func-
tion and reduce perioperative mortality and morbidity.1 The Lung Cancer Study
Group conducted a randomized trial of limited lung resection and lobectomy and
found a higher postoperative mortality and incidence of recurrence in the limited
resection group. On the basis of these findings, the group reported that lobectomy
should be performed even for T1 N0 M0 NSCLC.2
However, as a result of the widespread adoption of a lung cancer mass-screening
system3 and the introduction of chest computed tomographic scanning into the
system,4 there has been a marked increase in the incidence of small-sized lung
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cancers in Japan.5 The possibility of cure by performing
limited resection for small-sized peripheral lung cancer has
thus begun to receive close attention.
On the basis of our experience with limited resection in
poor-risk patients, we concluded that it might be possible to
radically cure peripheral small-sized lung cancer by means
of limited resection. In 1992, we began a pilot study of
limited resection for patients with cT1 N0 M0 NSCLC
whose maximum tumor diameter was 2 cm or less on
diagnostic imaging who provided informed consent for the
procedure.
This article retrospectively assesses the results of limited
resection and standard lobectomy in patients with T1 N0
NSCLC (tumor diameter of 2 cm) at the Niigata Cancer
Center.
Patients and Methods
Expecting that intentional limited resection for small-sized lung
cancer might provide an even postoperative survival compared
with lobectomy, in January 1992, we began enrolling patients who
satisfied the following criteria as candidates for this procedure: (1)
cT1 N0 M0 peripheral lung cancer with a tumor located relatively
closer to the visceral pleura than to the hilum; (2) maximum tumor
diameter of 2 cm or less as measured on plain chest x-ray film or
chest computed tomographic images; (3) no history of previous
treatment; (4) NSCLC; (5) general condition and respiratory func-
tion adequate for lobectomy; and (6) tumor location suitable for
limited resection (ie, the tumor was completely resectable with 1 or
3 segmentectomies, excluding the one located in the right middle
lobe).
A total of 268 candidates satisfied these criteria, and 80 of them
gave consent for limited resection. Limited resection was per-
formed in 76 patients, whereas the procedure was changed to
lobectomy in 4 patients in whom intraoperatively positive lymph
node metastasis was detected. Standard lobectomy was performed
in those from whom consent to limited resection was not obtained.
The subjects of this retrospective study were patients who satisfied
the above criteria, who were treated surgically at the Niigata
Cancer Center during the 9-year period from January 1992 to
December 2000, and whose tumors were postoperatively staged as
pT1 N0 M0 NSCLC (maximum tumor diameter in the resected
specimen of 2 cm).
The following patients were excluded from this study: 14
patients with pathologic positive lymph node metastasis; 9 patients
with a maximum tumor diameter measured in the resected speci-
mens of greater than 2 cm; 6 patients with positive lymph node
metastasis and large tumor size; 4 patients with pleural invasion;
and 2 patients with dissemination.
The operative procedure was limited resection in 74 patients
and pulmonary lobectomy in 159 patients. Local recurrence was
defined as recurrence at the surgical margin or within the operated
thoracic cavity (eg, malignant pleural effusion or lymph node
metastasis). Intrapulmonary metastasis or metastasis to other or-
gans was defined as distant metastasis.
The significance of differences in background variables be-
tween the 2 groups was tested by using the 2 or unpaired t tests.
Survival and disease-free survival period were calculated by using
the Kaplan-Meier method. The significance of differences in these
rates was tested by using the log-rank test.
Results
In the limited resection group the procedure of first choice
was segmentectomy. Incidentally, wedge resection was se-
lected when the space was 2 cm or wider between the tumor
edge and a surgical margin. Segmentectomy was performed
in 60 patients, and wedge resection was performed in 14
patients (Table 1). Lymph node dissection consisted of
complete hilar and mediastinal lymphadenectomy in 48
patients and incomplete lymphadenectomy in 26 patients. In
these 26 patients mediastinal lymphadenectomy was omit-
ted because no lymph node metastasis was detected after
sampling of the hilar lymph node. Recently, in Japan, when
the operator judges intraoperatively that there is no lymph
node metastasis in cases of early stage lung cancer, medi-
astinal lymphadenectomy is performed less frequently.
Among the background variables, male/female ratio, age,
TABLE 1. Background
Limited resection Lobectomy P value
No. of patients 74 159
Sex (M/F) 38/36 80/79 .77
Age (y) 64.2 7.2 65.3 9.5 .37
Tumor size (cm) 1.5 0.4 1.7 0.4 .001
Pulmonary function
VC/m2 (L) 2.07 0.44 1.99 0.41 .22
FEV1.0/m
2 (L) 1.48 0.36 1.46 0.32 .75
Histologic type .54
Adenocarcinoma 68 141
Squamous cell carcinoma 5 17
Other 1 1
Lymph node dissection .63
Complete 48 98
Incomplete 26 61
VC, Vital capacity; FEV, forced expiratory volume.
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pulmonary function, and histologic type did not differ sig-
nificantly between the limited resection group and the lo-
bectomy group, but maximum tumor diameter measured in
the resected specimens was significantly smaller in the
limited resection group (1.5  0.5 cm) than in the lobec-
tomy group (1.7  0.5 cm). There were no severe cardio-
vascular or comorbid factors in either group.
Follow-up was performed every 3 months for 5 years
after the operation, with chest radiography and hematologic
examination, and chest computed tomographic scans were
performed every year. The patients were followed up for 8
to 120 months (mean, 52 months). The 3-year and 5-year
survivals were slightly higher in the lobectomy group
(97.0% at 3 years and 90.1% at 5 years) than in the limited
resection group (94.0% and 89.1%, respectively), but the
differences were not statistically significant (Figure 1). The
95% confidence interval of the survival curve of patients
treated with lobectomy was 82.2% to 97.9%, and that of
patients treated with limited resection was 77.3% to 100%.
Recurrence was detected in 5 patients in the limited
resection group, including 2 cases of local recurrence (one
case each of malignant pleural effusion and ipsilateral me-
diastinal lymph node recurrence). Recurrence was diag-
nosed in 9 patients in the lobectomy group, including 2
cases of local recurrence (one case each of ipsilateral me-
diastinal lymph node recurrence and malignant pleural ef-
fusion), as shown in Table 2. No perioperative deaths were
recorded in either group. To date, 8 patients in the limited
resection group have died (including 5 deaths related to the
primary cancer), and 16 patients in the lobectomy group
have died (including 8 deaths related to the primary cancer).
The mortality rate did not differ significantly in the 2
groups, and as shown in Figure 2, there were no significant
differences in the 3-year and 5-year disease-free survivals
(limited resection group, 92.7% at 3 years and 88.7% at 5
years; lobectomy group, 94.2% at 3 years and 89.8% at 5
years).
Discussion
Lobectomy is usually performed to treat stage I peripheral
lung cancer. Limited pulmonary resection has been at-
tempted by many surgeons in patients with minimal tumor
invasion, expecting that this procedure would result in rad-
ical cure of the cancer. Because limited resection imposes
less operative stress on the patient (smaller lung volume
resected and shorter operation time), it has primarily been
performed in patients in relatively poor general condition
due to compromised lung function.1
Errett and coworkers6 performed wedge resection in 100
poor-risk patients with stage I lung cancer (elderly patients
and patients with compromised lung function) and reported
that the 6-year survival in these patients (69%) did not differ
significantly from that of patients treated with lobectomy
(75%) (Table 3).2,6-12
Pastorino and coworkers7 also performed limited resec-
tion in 61 poor-risk patients with stage I lung cancer and
then reported a 5-year survival of 55% in this group com-
pared with 49% in a pulmonary lobectomy group. The
patients with T1 disease treated with limited resection in
Figure 2. Postoperative disease-free survival curve. There was no
significant difference in disease-free survivals of patients treated
with limited resection and those treated with lobectomy (P .93).
TABLE 2. Clinical outcome
Limited resection Lobectomy P value
Follow-up period (d) 1624 681 1532 966 .47
Recurrence 5 9 .74
Local 2 2 .42
Distant 3 7 .90
Death 8 16 .86
Lung cancer 5 8 .59
Other disease 3 8 .73
Figure 1. Postoperative survival curve. There was no significant
difference in the survivals of patients treated with limited resec-
tion and those treated with lobectomy (P  .91). Figures given in
parentheses indicate censored cases.
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particular had a higher 5-year survival (73%) than those
treated with lobectomy (55%), and on the basis of these
results, they reported that limited resection is an effective
procedure for the treatment of T1 disease.
Read and associates8 intentionally performed limited re-
section in low-risk patients, and they reported a higher
5-year survival in 113 patients with T1 N0 M0 lung cancer
treated with limited resection than in 131 similar patients
treated with lobectomy.
Warren and colleagues9 compared 66 patients with stage
I disease treated by means of limited resection with 103
patients with stage I disease treated by means of lobectomy
and reported that the 5-year survival was significantly
higher in the lobectomy group when the tumor diameter was
3 cm or greater but that lobectomy was not superior when
the maximum tumor diameter was less than 3 cm. Their
findings suggest that limited resection can be used as the
standard procedure for the surgical treatment of T1 N0 lung
cancer.
However, in 1995, after conducting a randomized con-
trolled trial involving limited resection and lobectomy, the
Lung Cancer Study Group concluded that lobectomy should
be performed as the standard procedure for all patients with
T1 N0 disease because limited resection is associated with
higher mortality and local recurrence rates.2
Landreneau and coworkers10 compared the results of
wedge resection in 102 patients with T1 N0 NSCLC with
the results of lobectomy in 117 similar patients. They re-
ported a 5-year survival of 58% in patients treated with open
wedge resection, 65% in patients treated with video-assisted
wedge resection, and 70% in patients treated with lobec-
tomy and concluded that lobectomy should be selected for
all but poor-risk patients. After publication of these reports,
it became difficult to select intentional limited resection for
low-risk patients with lung cancer in the United States.
In Japan, the lung cancer mass-screening program sup-
ported by the national government under the Health and
Medical Services Law for the Aged was started in 1987.3
After the nationwide implementation of this mass-screening
program, sometimes combined with chest computed tomo-
graphic scanning, the number of patients given a diagnosis
of small-sized lung cancer has been increasing. Faced with
this situation, in 1992, Tsubota and colleagues11 began a
multi-institutional clinical study of treatment of T1 N0
NSCLC (maximum tumor diameter 2 cm) with segmen-
tectomy. Fifty-five patients were enrolled in the study dur-
ing the first 3 years, and among the patients followed up for
a mean of 47 months, the 5-year survival exclusive of deaths
unrelated to the lung cancer was 91%.
Kodama and coworkers12 conducted a retrospective anal-
ysis of patients with T1 N0 M0 lung cancer, 46 of whom
had undergone limited resection and 77 of whom had un-
dergone lobectomy. They found that although the tumor
diameter tended to be smaller in the limited resection group,
the 5-year survival was higher in the limited resection group
(93% vs 88% in the lobectomy group). They therefore
concluded that segmentectomy should be considered an
acceptable treatment procedure in such patients.
In 1992, we began to perform intentional limited resec-
tion for patients in our institution with T1 N0 M0 lung
cancer whose maximum tumor diameter was 2 cm or less.
Although tumor diameter tended to be smaller in the limited
resection group, the 5-year survival in the limited resection
group of 89.1% was comparable to that in the lobectomy
group (90.1%).
Yamato and coworkers13 conducted limited resection in
36 patients with adenocarcinoma with tumors smaller than 2
cm that did not show a marked tendency to infiltrate, and
they reported no tumor recurrence during an average fol-
low-up period 30 months.
TABLE 3. Survival and local recurrence rate in reported series of limited resection
Reference/period Subject
Limited resection Lobectomy
No. of
patients
5 y
survival (%)
Local
recurrence (%)
No. of
patients
5 y
survival (%)
Local recurrence
(%)
Erreett6 1965-’82 Stage I (C) 100 69 NM 97 75 NM
Pastorino7 1971-’88 Stage I (C) 61 55 5 411 49 5
Read8 1966-’88 T1 N0 M0 (I) 113 about 84 4.4 131 about 74 11.5
Warren9 1980-’88 Stage I (I) 66 about 43 22.7 103 about 67 4.9
LCSG2 1982-’88 T1 N0 M0 (R) 122 44 17.2 125 65 6.4
Landreneau10 1989-’94 T1 N0 M0 (C) 42* 58 24 117 70 9
60† 65 16
Tsubota11 1992-’94 T1 N0 M0‡ (I) 55 91§ 5.5 NM NM
Kodama12 1985-’96 T1 N0 M0 (I) 46 93 2.2 77 88 1.3
Koike 1992-2000 T1 N0 M0‡ (I) 74 89 2.7 159 90 1.3
C, Compromised, I, intentional; R, randomized controlled trial; NM, not mentioned.
*Open wedge resection.
†Video-assisted wedge resection.
‡Maximum tumor diameter 2 cm.
§Death rate related to primary lung cancer.
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It was previously thought that the incidence of local
recurrence after limited resection would be higher than that
after lobectomy, but recent studies, including the present
study, have shown that the incidence of local recurrence
after limited resection is not significantly higher than that
after lobectomy.11,13
On the basis of these numerous reports, it can be con-
cluded that some cases of T1 N0 M0 lung cancer can be
completely resected by means of limited resection.
There were some reports concerning the relationship
between prognosis and tumor histologic characteristics in
adenocarcinoma. Noguchi and associates14 classified small-
sized adenocarcinoma (tumor 2 cm) into 6 types on the
basis of their histopathologic features and reported that the
prognosis of types A and B, characterized by replacement of
the alveolar epithelium by cancer cells and absence of active
fibroblastic proliferation, is good, with a postoperative
5-year survival of 100%. Suzuki and coworkers15 reported
that the size of central fibrosis was an independent prog-
nostic factor in peripheral lung adenocarcinoma.
A randomized controlled study to assess the effective-
ness of limited resection compared with lobectomy in the
treatment of T1 N0 M0 lung cancer would be worthwhile,
but there remains the question of which patients should be
selected for this study, patients with a lower degree of
infiltration (as judged by diagnostic imaging) or patients
with small tumor diameters.
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